Production of adeno-associated virus vectors for in vitro and in vivo applications.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
19 09 2019
Historique:
received: 18 09 2018
accepted: 11 07 2019
entrez: 21 9 2019
pubmed: 21 9 2019
medline: 27 10 2020
Statut: epublish

Résumé

Delivering and expressing a gene of interest in cells or living animals has become a pivotal technique in biomedical research and gene therapy. Among viral delivery systems, adeno-associated viruses (AAVs) are relatively safe and demonstrate high gene transfer efficiency, low immunogenicity, stable long-term expression, and selective tissue tropism. Combined with modern gene technologies, such as cell-specific promoters, the Cre/lox system, and genome editing, AAVs represent a practical, rapid, and economical alternative to conditional knockout and transgenic mouse models. However, major obstacles remain for widespread AAV utilization, such as impractical purification strategies and low viral quantities. Here, we report an improved protocol to produce serotype-independent purified AAVs economically. Using a helper-free AAV system, we purified AAVs from HEK293T cell lysates and medium by polyethylene glycol precipitation with subsequent aqueous two-phase partitioning. Furthermore, we then implemented an iodixanol gradient purification, which resulted in preparations with purities adequate for in vivo use. Of note, we achieved titers of 10

Identifiants

pubmed: 31537820
doi: 10.1038/s41598-019-49624-w
pii: 10.1038/s41598-019-49624-w
pmc: PMC6753157
doi:

Substances chimiques

Glrx protein, mouse 0
Glutaredoxins 0
Polyethylenes 0
RNA, Small Interfering 0
polyethylene chloride 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

13601

Subventions

Organisme : NHLBI NIH HHS
ID : T32 HL007224
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL133013
Pays : United States
Organisme : NIA NIH HHS
ID : R03 AG051857
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK103750
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001430
Pays : United States

Références

J Virol. 1971 Dec;8(6):860-63
pubmed: 5172922
Hum Gene Ther Methods. 2012 Feb;23(1):18-28
pubmed: 22428977
Redox Biol. 2017 Aug;12:462-468
pubmed: 28334681
Hum Gene Ther. 2009 Jul;20(7):698-706
pubmed: 19438300
Nat Rev Genet. 2014 Jul;15(7):445-51
pubmed: 24840552
Drug Healthc Patient Saf. 2017 May 22;9:25-37
pubmed: 28579836
Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5103-6
pubmed: 12697895
Cytotechnology. 2010 Jan;62(1):73-82
pubmed: 20309632
EMBO J. 1992 Dec;11(13):5071-8
pubmed: 1334463
Vaccine. 2016 Dec 7;34(50):6323-6329
pubmed: 27817961
Cytotechnology. 2013 Jan;65(1):135-43
pubmed: 22695857
Mol Ther. 2009 Jan;17(1):144-52
pubmed: 18941440
J Biol Methods. 2016;3(2):
pubmed: 27294171
Hum Gene Ther. 2009 Sep;20(9):1013-21
pubmed: 19534598
J Virol. 2008 Jun;82(12):5887-911
pubmed: 18400866
Bioengineered. 2013 Mar-Apr;4(2):103-6
pubmed: 22992716
Curr Opin Pharmacol. 2017 Jun;34:56-63
pubmed: 28743034
Am J Physiol. 1991 Aug;261(2 Pt 1):G185-90
pubmed: 1872392
Nat Protoc. 2006;1(3):1412-28
pubmed: 17406430
Cell Metab. 2016 Apr 12;23(4):663-74
pubmed: 27050306
Mol Ther. 2009 Aug;17(8):1427-33
pubmed: 19471246
J Biol Chem. 1979 Apr 25;254(8):2669-76
pubmed: 429309
J Virol. 2014 Apr;88(8):4366-74
pubmed: 24501408
J Virol. 2012 Nov;86(21):11877-85
pubmed: 22915820
Hum Gene Ther. 2010 Oct;21(10):1251-7
pubmed: 20649475
Ann Thorac Surg. 1996 Dec;62(6):1669-76
pubmed: 8957370
Hum Gene Ther Methods. 2016 Feb;27(1):32-45
pubmed: 26863210
Free Radic Biol Med. 2011 Sep 15;51(6):1249-57
pubmed: 21762778
Hum Gene Ther. 2010 Oct;21(10):1259-71
pubmed: 20497038
J Virol. 1998 Nov;72(11):8568-77
pubmed: 9765395
Circ Res. 2013 Jan 18;112(2):382-92
pubmed: 23329793
Mol Ther Methods Clin Dev. 2016 Mar 30;3:16015
pubmed: 27069949
J Biol Chem. 2007 Apr 27;282(17):12467-74
pubmed: 17324929
Curr Gene Ther. 2015;15(4):381-94
pubmed: 26122097
Lancet. 2007 Jun 23;369(9579):2097-105
pubmed: 17586305
J Gene Med. 2004 Jul;6(7):715-23
pubmed: 15241778
Antioxid Redox Signal. 2017 Aug 20;27(6):313-327
pubmed: 27958883
Methods Enzymol. 2002;346:413-30
pubmed: 11883083
Gene Ther. 2010 Apr;17(4):503-10
pubmed: 19956269
Hum Gene Ther. 2016 Dec;27(12):947-961
pubmed: 27897038
Hum Gene Ther Methods. 2015 Jun;26(3):82-92
pubmed: 25953194
Hum Gene Ther Methods. 2012 Feb;23(1):1-7
pubmed: 22428975
J Virol. 1988 Aug;62(8):2745-54
pubmed: 2839699
Hum Gene Ther. 1999 Jul 20;10(11):1885-91
pubmed: 10446928
Mol Ther. 2017 Jun 7;25(6):1363-1374
pubmed: 28462820
Hum Gene Ther. 1997 Apr 10;8(6):659-69
pubmed: 9113506
Proc Natl Acad Sci U S A. 2016 May 24;113(21):6011-6
pubmed: 27162359
Dev Cell. 2016 Mar 7;36(5):540-9
pubmed: 26954548
Hum Gene Ther. 1999 Oct 10;10(15):2445-50
pubmed: 10543610
Nat Med. 2006 Jul;12(7):787-9
pubmed: 16819550
N Engl J Med. 2008 May 22;358(21):2231-9
pubmed: 18441371
Hum Gene Ther Methods. 2012 Jun;23(3):198-203
pubmed: 22816378
Mol Ther Methods Clin Dev. 2016 Mar 30;5:16019
pubmed: 27069952
J Virol Methods. 2012 Aug;183(2):139-46
pubmed: 22561982
Gene Ther. 1999 Jun;6(6):973-85
pubmed: 10455399
Diabetes Obes Metab. 2018 Aug;20(8):1928-1936
pubmed: 29652108
Yonsei Med J. 2016 May;57(3):790-4
pubmed: 26996583
Redox Biol. 2017 Aug;12:1011-1019
pubmed: 28505880
N Engl J Med. 2017 Dec 28;377(26):2519-2530
pubmed: 29224506
Acta Radiol. 1993 Jan;34(1):72-7
pubmed: 8427753
Mol Ther Methods Clin Dev. 2018 Jul 27;10:223-236
pubmed: 30112419
Antioxid Redox Signal. 2008 Nov;10(11):1941-88
pubmed: 18774901
Nucleic Acids Res. 2003 Sep 1;31(17):e100
pubmed: 12930974
J Biol Chem. 2008 Jul 18;283(29):20015-26
pubmed: 18482975
Antioxid Redox Signal. 2012 Mar 15;16(6):524-42
pubmed: 22010840
Vascular. 2016 Jun;24(3):273-8
pubmed: 26126996

Auteurs

Toyokazu Kimura (T)

Vascular Biology Section, Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, USA.
Cardiovascular Medicine, National Defense Medical College, Tokorozawa, Japan.

Beatriz Ferran (B)

Vascular Biology Section, Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, USA.

Yuko Tsukahara (Y)

Vascular Biology Section, Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, USA.

Qifan Shang (Q)

Vascular Biology Section, Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, USA.

Suveer Desai (S)

Vascular Biology Section, Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, USA.

Alessandra Fedoce (A)

Vascular Biology Section, Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, USA.

David Richard Pimentel (DR)

Cardiology, Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, USA.

Ivan Luptak (I)

Cardiology, Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, USA.

Takeshi Adachi (T)

Cardiovascular Medicine, National Defense Medical College, Tokorozawa, Japan.

Yasuo Ido (Y)

Cardiovascular Medicine, National Defense Medical College, Tokorozawa, Japan.

Reiko Matsui (R)

Vascular Biology Section, Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, USA. rmatsui@bu.edu.

Markus Michael Bachschmid (MM)

Vascular Biology Section, Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, USA. bach@bu.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH